Clinical Trials Directory

Trials / Completed

CompletedNCT00966225

LIP-01 in Hypercholesterolemia

An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Afexa Life Sciences Inc · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine a safe and tolerable dose of LIP-01

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLIP-01comparison of different dosages of natural health product

Timeline

Start date
2009-09-01
Primary completion
2012-01-01
Completion
2012-01-01
First posted
2009-08-26
Last updated
2012-01-31

Locations

2 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT00966225. Inclusion in this directory is not an endorsement.

LIP-01 in Hypercholesterolemia (NCT00966225) · Clinical Trials Directory